Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.57 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6390959 | 0.79 | CXCR2 (0.58) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL489710 | 0.73 | CXCR2 (0.67) | CXCR2 | |
| SCHEMBL4225334 | 0.72 | CXCR2 (1.00) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL4373934 | 0.70 | HPGD (0.69) | CXCR2 | |
| SCHEMBL842322 | 0.68 | CXCR2 (0.70) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL13980530 | 0.67 | CXCR2 (0.41) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3855926 | 0.65 | CXCR2 (0.45) | CXCR2 | |
| SCHEMBL4373932 | 0.65 | CXCR2 (0.54) | CXCR2CHRM5CX3CR1 | |
| SCHEMBL3852995 | 0.65 | CXCR2 (0.49) | CXCR2 | |
| SCHEMBL6868847 | 0.65 | CXCR2 (0.69) | CXCR2CHRM5CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-7585867-B2 | Substituted thiazolo[4,5-d]pyrimidin-2(3H)-one | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| EP-1542974-B1 | 5-[((2,3-difluorophenyl)methyl)thio]-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| EP-1543013-B1 | 5-[[(2,3-Difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one monosodium salt as CXCR2 antagonist | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20080306262-A1 | Novel Compound | ASTRAZENECA AB, A SWEDISH CORPORATION | 2008-12-11 | — | — | US | disclosed |
| US-20060100221-A1 | Novel compound | ASTRAZENECA AB (SE) | 2006-05-11 | — | — | US | disclosed |
| EP-1543013-A1 | NOVEL COMPOUND | Astrazeneca AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004026880-A1 | NOVEL COMPOUND | ASTRAZENECA AB (SE) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100221-A1 | Novel compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885CHRM5 3941/4885CX3CR1 2854/4885 |
| US-20080306262-A1 | Novel Compound | SLC10A1, AVPR2, NPC1 | CXCR2 156/4885CHRM5 3941/4885CX3CR1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.